{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:55:19Z","timestamp":1787316919897,"version":"build-2736575974"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Clinical Assessment Scale for Autoimmune Encephalitis (CASE), a new scale used for rating the severity of autoimmune encephalitis (AE), has demonstrated good validity and reliability in adults with AE, but there is a shortage of data on its performance in children with AE. This study aimed to assess the reliability and validity of the CASE in a cohort of children with AE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Forty-seven pediatric inpatients with AE who visited Guizhou Provincial People\u2019s Hospital between January 1, 2017, and October 31, 2021, were enrolled in the study. The CASE and mRS scores were obtained through a review of detailed medical records from the Health Information System by two pediatric neurologists. Finally, the performance of the CASE in this pediatric AE cohort was analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The results showed that anti-NMDA receptor encephalitis was the most common (61.70%) type of AE in children. The most common clinical manifestations were language problems (85.1%), psychiatric symptoms (80.9%), and dyskinesia\/dystonia (78.7%). The CASE had good item reliability and interevaluator reliability; the Cronbach\u2019s alpha value of the total score was 0.825, and the intraclass correlation (ICC) was 0.980. The Cronbach\u2019s alpha value by item ranged from 0.16 to 0.406; items 1 and 9 had the lowest and highest Cronbach\u2019s alpha values, respectively. The criterion validity between CASE and mRS total scores, as quantified by Pearson correlation, was 0.459, indicating slight to good criterion validity. The area under the curve (AUC) was 0.992 (95% confidence interval: 0.974-1.00). A cutoff value of 14 was selected to determine whether a patient needed admission to the ICU; this cutoff had a sensitivity of 100% and a specificity of 92%. The changes in EEG, MRI, and antibody titers were not related to the severity of AE. A CASE score cutoff of 9 was selected to indicate whether second-line treatment would be needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The CASE has good reliability and validity in children with AE; however, some items of the CASE may not apply to this population. Thus, an in-depth study of the CASE is needed in children with AE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2022.915352","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:39:50Z","timestamp":1665707990000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Performance of the clinical assessment scale for autoimmune encephalitis in a pediatric autoimmune encephalitis cohort"],"prefix":"10.3389","volume":"13","author":[{"given":"Hao","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zailan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoqing","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifeng","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-mediated encephalitis","volume":"378","author":"Dalmau","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"577598","DOI":"10.1016\/j.jneuroim.2021.577598","article-title":"Epidemiology of neuronal surface antibody-mediated autoimmune encephalitis and antibody-based diagnostics","volume":"357","author":"Zuliani","year":"2021","journal-title":"J NEUROIMMUNOL"},{"key":"B3","doi-asserted-by":"publisher","first-page":"577753","DOI":"10.1016\/j.jneuroim.2021.577753","article-title":"The changing spectrum of antibody-mediated encephalitis in China","volume":"361","author":"Ren","year":"2021","journal-title":"J NEUROIMMUNOL"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25131","article-title":"Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis","volume":"83","author":"Dubey","year":"2018","journal-title":"Ann Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.803854","article-title":"The antibody assay in suspected autoimmune encephalitis from positive rate to test strategies","volume":"13","author":"Deng","year":"2022","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006990","article-title":"Autoimmune encephalitis: A costly condition","volume":"92","author":"Cohen","year":"2019","journal-title":"NEUROLOGY"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2020-0241","article-title":"Update on the diagnosis and management of autoimmune encephalitis","volume":"20","author":"Ellul","year":"2020","journal-title":"Clin Med (Lond)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1590\/0004-282x20170176","article-title":"Autoimmune encephalitis: A review of diagnosis and treatment","volume":"76","author":"Dutra","year":"2018","journal-title":"Arq Neuropsiquiatr"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2174\/1871527319666200708133103","article-title":"Autoimmune encephalitis: Current knowledge on subtypes, disease mechanisms and treatment","volume":"19","author":"Nissen","year":"2020","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000449","article-title":"Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis","volume":"30","author":"Spatola","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s12883-021-02520-1","article-title":"Clinical characteristics and prognosis of anti-alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic acid receptor encephalitis","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000514","article-title":"Management and prognostic markers in patients with autoimmune encephalitis requiring ICU treatment","volume":"6","author":"Schubert","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.19.5.604","article-title":"Interobserver agreement for the assessment of handicap in stroke patients","volume":"19","author":"van Swieten","year":"1988","journal-title":"STROKE"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25421","article-title":"Development of the clinical assessment scale in autoimmune encephalitis","volume":"85","author":"Lim","year":"2019","journal-title":"Ann Neurol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s40120-021-00278-9","article-title":"Validation of the clinical assessment scale for autoimmune encephalitis: A multicenter study","volume":"10","author":"Cai","year":"2021","journal-title":"Neurol Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.796965","article-title":"Validation of the clinical assessment scale in autoimmune encephalitis in Chinese patients","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2021.01.001","article-title":"Clinical features of pediatric and adult autoimmune encephalitis: A multicenter sample","volume":"30","author":"Roliz","year":"2021","journal-title":"Eur J Paediatr Neurol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e663","DOI":"10.1212\/NXI.0000000000000663","article-title":"Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient","volume":"7","author":"Cellucci","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e633","DOI":"10.1212\/NXI.0000000000000633","article-title":"Anti-NMDAR encephalitis: A single-center, longitudinal study in China","volume":"7","author":"Xu","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00406-020-01113-2","article-title":"Autoimmune encephalitis as a differential diagnosis of schizophreniform psychosis: clinical symptomatology, pathophysiology, diagnostic approach, and therapeutic considerations","volume":"270","author":"Endres","year":"2020","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.621599","article-title":"Neuronal surface antibody-medicated autoimmune encephalitis (Limbic encephalitis) in China: A multiple-center, retrospective study","volume":"12","author":"Shan","year":"2021","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.611597","article-title":"Clinical characteristics and outcome of neuronal surface antibody-mediated autoimmune encephalitis patients in a national cohort","volume":"12","author":"Hayden","year":"2021","journal-title":"Front Neurol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jaut.2018.10.014","article-title":"Prognosticating autoimmune encephalitis: A systematic review","volume":"96","author":"Broadley","year":"2019","journal-title":"J AUTOIMMUN"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.642078","article-title":"Characteristics and prognosis of autoimmune encephalitis in the East of China: A multi-center study","volume":"12","author":"Qiao","year":"2021","journal-title":"Front Neurol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70282-5","article-title":"Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: A retrospective study","volume":"13","author":"Gresa-Arribas","year":"2014","journal-title":"Lancet Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.915352\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:39:53Z","timestamp":1665707993000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.915352\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,14]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2022.915352"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.915352","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,14]]},"article-number":"915352"}}